MCOLN2 and glioma: The low TRPML-2 expression in normal brain and the progressive overexpression in low vs high grade gliomas may give TRPML-2 channels as predictive and specific biomarker in brain tumors of astrocyte origin [43] and may point to novel approaches in glioma therapy.